Asian Cohort for Alzheimer's Disease (ACAD)

项目摘要 阿尔茨海默病（AD）影响美国580万人，是我们国家的巨大负担。 经济、患者和护理人员。全基因组关联研究（GWAS）已成功地导致25个 与AD风险相关的全基因组显著位点以及与关键临床协变量的更多相关性。 大多数这些发现都是对欧洲血统的参与者进行的，尽管研究其他人的努力， 少数民族人口正在增加。亚裔美国人对AD遗传学的了解尤其有限 由于缺乏参与者。亚裔美国人占美国人口的6%，但他们的样本不足， 值得更多的科学投资。 我们提出了阿尔茨海默病亚洲队列（ACAD），第一个大型阿尔茨海默病（AD） 美国（US）和加拿大的亚洲人遗传学队列。为了优化ACAD的成功，我们组装了一个 科学家、临床医生和社区合作伙伴的团队，在AD研究方面具有合作历史和专业知识， 人类遗传学和亚洲社区外展。我们建议招募5，970名60岁或以上的参加者， 来自美国和加拿大大都市地区的中国、韩国和越南血统的老年人， 与社区合作伙伴、诊所或为亚裔社区服务的疗养院合作。我们将收集 唾液中的DNA，并使用经验证的本地化仪器、数据表和临床/诊断方案。到 为了支持这些招募和数据收集活动，我们将建立一个协调中心， 管理、社区外展和培训计划，以支持招募和分析活动，以及 对征聘和外联工作进行流程评价。将使用SNP对所有样本进行基因分型 阵列，并使用来自亚洲的全基因组测序数据的大型亚洲特异性参考面板进行插补。 亚洲国际集团我们将分析遗传和临床数据，以调查生活方式风险的影响 因素，AD风险的遗传变异，评估性别和APOE基因型对AD风险的不同影响， 使用遗传和生活方式风险评分预测AD的临床诊断。我们将通过以下方式复制这些发现： 与国际亚洲队列和其他人群AD研究的荟萃分析合作。 亚裔美国人占美国人口的6%，抽样不足，应该得到更多的科学研究 对阿尔茨海默病研究的投资。ACAD项目将建立第一个主要的AD遗传学研究， 在美国和加拿大的亚洲人。成功完成将导致新的遗传和生活方式筛选标记 为亚裔美国人和见解的新的治疗目标，为AD。ACAD将是第一个网络， 在亚裔美国人中招募和学习广告，将扩展到亚洲印度人，菲律宾人和其他亚洲人 未来的美国人口，为亚洲阿尔茨海默病研究的未满足需求服务 美国人

Project Summary Alzheimer's disease (AD) affects 5.8 million people in the United States and is an immense burden on our economy, patients and caregivers. Genome-wide association studies (GWAS) have successfully led to 25 genome-wide significant loci associated with AD risk and many more associations with key clinical covariates. Most of these findings are made on participants with European ancestry, although efforts to study other minority populations are taking off. Knowledge about AD genetics among Asian Americans is especially limited due to lack of participants. Comprising 6% of the US populace, Asian Americans are under-sampled and deserve more scientific investment. We propose the Asian Cohort for Alzheimer's Disease (ACAD), the first large Alzheimer's Disease (AD) genetics cohort for Asians in United States (US) and Canada. To optimize ACAD's success, we assembled a team of scientists, clinicians, and community partners with collaborative history and expertise in AD research, human genetics, and Asian community outreach. We propose to recruit 5,970 participants aged 60 years or older and of Chinese, Korean, and Vietnamese ancestry from metropolitan areas across the US and Canada in collaboration with community partners, clinics, or nursing homes that serve Asian communities. We will collect saliva for DNA and use validated, localized instruments, data forms, and clinical/diagnostic protocols. To support these recruitment and data collection activities, we will set up a coordinating center and develop governance, community outreach and training programs to support recruitment and analysis activities, and conduct a process evaluation of the recruitment and outreach efforts. All samples will be genotyped using SNP arrays and imputed using a large Asian-specific reference panel of whole genome sequencing data from international Asian cohorts. We will analyze genetic and clinical data to investigate impact of lifestyle risk factors, genetic variants for AD risk, evaluate differential effects of sex and APOE genotypes on AD risk, and predict clinical diagnosis of AD using genetic and lifestyle risk scores. We will replicate these findings through meta-analysis collaborations with international Asian cohorts and AD studies from other populations. Comprising 6% of the US populace, Asian Americans are under-sampled and deserve more scientific investment in Alzheimer's disease research. The ACAD project will build the first major AD genetics study for Asians in the US and Canada. Successful completion will lead to new genetic and lifestyle screening markers for Asian Americans and insights about novel therapeutic targets for AD. ACAD will be a first network for recruiting and studying AD in Asian Americans that will extend to Asian Indians, Filipino and other Asian American populations in the future, serving the unmet needs of Alzheimer's disease research for Asian Americans.